July 01, 2010
Phase 1 and 2 studies of antisense therapy for type 2 diabetesIsis Pharmaceuticals announced the presentation of data from its clinical trials of ISIS 113715 and ISIS-GCGRRx for the treatment of diabetes. In a Phase 2 study, ISIS 113715 demonstrated improvements in glycemic control and dyslipidemia, as well as an increase in adiponectin levels in type 2 diabetic patients uncontrolled on stable sulfonylurea therapy. The study demonstrated statistically significant reductions in multiple short and intermediate measures of glucose control at the 200 mg/week dose, a decrease of approximately 11 mg/dL in LDL cholesterol and a reduction in body weight that was preceded by a statistically significant increase in circulating adiponectin.
In a Phase 1 study of ISIS-GCGRRx, patients were given a glucagon challenge that doubled both plasma glucagon and glucose levels. ISIS-GCGRRx showed a statistically significant improvement in blood glucose levels and reduced liver glucose production following a glucagon challenge at a dose of 400 mg/week.
ISIS 113715 is a novel antisense PTP-1B inhibitor being studied in combination with other commonly prescribed type 2 diabetes drugs. ISIS-GCGRRx is an antisense drug being studied for its therapeutic potential of inhibiting the glucagon receptor. Glucagon is believed to play a greater role in increasing blood glucose in patients with advanced diabetes.
For more information call (760) 931-9200 or visit www.isispharm.com.